Congress trades and big insider sales, sent the day they're filed. Free.
Open in Telegram
Chief Financial Officer · Niagen Bioscience, Inc. · Common Stock
Open-market purchase
$30K reported value · 153.6% of prior position
Disclosed 1 business day after execution (deadline: 2)
First recorded trade by this actor in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | YU Wing Tak WendyDirector | Grant or award | A | — 31.7K sh | Jun 26, 2026 traded Jun 24, 2026 | |
| 9 | Patrick KristinDirector | Grant or award | A | — 31.7K sh | Jun 26, 2026 traded Jun 24, 2026 | |
| 9 | Cohen AnnDirector | Grant or award | A | — 31.7K sh | Jun 26, 2026 traded Jun 24, 2026 | |
| 9 | Ng Wang Yu GaryDirector | Grant or award | A | — 31.7K sh | Jun 26, 2026 traded Jun 24, 2026 | |
| 9 | Shahbazi HamedDirector | Grant or award | A | — 31.7K sh | Jun 26, 2026 traded Jun 24, 2026 | |
| 41 | Pamir OzanChief Financial Officer | Open-market purchase | BUY | $15K 2,220 sh | Nov 17, 2025 traded Nov 14, 2025 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $30,406
Pamir Ozan filed this Form 4 reporting a open-market purchase of NAGE on Nov 14, 2025. It became public on Nov 17, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.